0.7360SEK+3.66%Mkt Cap: 235.88M SEKP/E: —Last update: 2026-06-01
Isofol Medical AB (publ) operates as a clinical stage biotech company. It develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. The company was incorporated in …
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap235.88M SEK
Enterprise Value88.85M SEK
Revenue (TTM)—
Gross Profit-40.16M SEK
Net Income (TTM)-54.17M SEK
Revenue/Share—
Last Price0.7360 SEK
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees6
CountrySE
SectorHealthcare
IndustryBiotechnology
ISINSE0009581051
Valuation
P/E (Trailing)—
P/E (Forward)-14.20
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B2.15
EPS (TTM)-0.22
EPS (Forward)-0.05
52W Range
0.551516% of range1.738
52W High1.738 SEK
52W Low0.5515 SEK
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-50.22%
ROA-41.86%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-51.94M SEK
CapEx (TTM)—
FCF Margin—
FCF Yield-15.23%
Net Debt-110.74M SEK
Net Debt/EBITDA—
Balance Sheet
Debt/Equity—
Current Ratio5.57
Quick Ratio5.50
Book Value/Sh0.3300 SEK
Cash/Share0.3940 SEK
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 SEK
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating0.0 (Hold)
Target (Mean)3.600 SEK
Target Range1.900 SEK – 5.300 SEK
# Analysts2
Ownership
Shares Out.320.49M
Float200.11M
Insiders20.28%
Institutions13.58%
Technical
SMA 500.6867 (+7.2%)
SMA 2000.7144 (+3.0%)
Beta0.92
S&P 52W Chg27.70%
Avg Vol (30d)587.24K
Avg Vol (10d)430.10K
Technical Indicators
RSI (14)52.4
MACD0.0071
MACD Signal0.0081
MACD Hist.-0.0011
BB Upper0.7485 SEK
BB Middle0.7022 SEK
BB Lower0.6558 SEK
BB Width13.21%
ATR (14)0.0403 SEK
Vol Ratio (20d)0.54x